Systematic (IUPAC) name | |
---|---|
2-[2-nitro-4-(trifluoromethyl)benzoyl] cyclohexane-1,3-dione |
|
Clinical data | |
AHFS/Drugs.com | Consumer Drug Information |
Licence data | EMA:Link, US FDA:link |
Pregnancy cat. | ? |
Legal status | ℞-only (US) |
Routes | Oral |
Pharmacokinetic data | |
Half-life | Approximately 54 h |
Identifiers | |
CAS number | 104206-65-7 |
ATC code | A16AX04 |
PubChem | CID 115355 |
DrugBank | APRD01141 |
ChemSpider | 103195 |
UNII | K5BN214699 |
KEGG | D05177 |
ChEBI | CHEBI:50378 |
ChEMBL | CHEMBL1337 |
Chemical data | |
Formula | C14H10F3NO5 |
Mol. mass | 329.228 g/mol |
SMILES | eMolecules & PubChem |
|
|
(verify) |
(what is this?)
Nitisinone (also known as NTBC, an abbreviation of its full chemical name) is a drug originally developed as an herbicide now used in the treatment of hereditary tyrosinemia type 1. Since its first use for this indication in 1991, it has replaced liver transplantation as the first-line treatment for this rare condition.[1] It is also being studied in the less severe but related condition alkaptonuria.[2] It is marketed under the brand name Orfadin.
The mechanism of action of nitrisinone involves reversibile inhibition of 4-hydroxyphenylpyruvate oxidase,[3] [4] thus preventing the formation of maleylacetoacetic acid and fumarylacetoacetic acid, which have the potential to be converted to succinyl acetone, a toxin that damages the liver and kidneys.[1]
Anon US application 19,920,903,691.
|